Immunic Ownership

IMUX Stock  USD 1.15  0.03  2.68%   
Immunic has a total of 90.08 Million outstanding shares. Over half of Immunic's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2012-09-30
Previous Quarter
101.3 M
Current Value
101.3 M
Avarage Shares Outstanding
16.5 M
Quarterly Volatility
25.7 M
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Immunic in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Immunic, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

Immunic Stock Ownership Analysis

About 59.0% of the company shares are owned by institutional investors. The book value of Immunic was currently reported as 0.46. The company recorded a loss per share of 1.23. Immunic last dividend was issued on the 15th of April 2019. The entity had 1:40 split on the 15th of April 2019. Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people. To learn more about Immunic call Daniel Vitt at 332 255 9818 or check out https://imux.com.
Besides selling stocks to institutional investors, Immunic also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Immunic's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Immunic's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Immunic Quarterly Liabilities And Stockholders Equity

64.76 Million

Only 1.03% of Immunic are currently held by insiders. Unlike Immunic's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Immunic's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Immunic's insider trades

Immunic Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Immunic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunic backward and forwards among themselves. Immunic's institutional investor refers to the entity that pools money to purchase Immunic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2024-12-31
952.3 K
Susquehanna International Group, Llp2024-12-31
883.7 K
Blackrock Inc2024-12-31
784.2 K
683 Capital Management Llc2024-12-31
700 K
Millennium Management Llc2024-12-31
579.7 K
Renaissance Technologies Corp2024-12-31
566.6 K
Boothbay Fund Management, Llc2024-12-31
425.3 K
Marshall Wace Asset Management Ltd2024-12-31
417.9 K
State Street Corp2024-12-31
303.9 K
Bvf Inc2024-12-31
8.9 M
Avidity Partners Management Lp2024-12-31
M
Note, although Immunic's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Immunic Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Immunic Outstanding Bonds

Immunic issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunic uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunic bonds can be classified according to their maturity, which is the date when Immunic has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunic Stock Analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.